EOSVISION

EOSVISION was founded in 2020, focusing on the development of innovative products using novel bio-modified materials for ophthalmic implant medical devices and regenerative medicine devices. The core founding team members have over fifteen years of R&D and management experience in international and domestic pharmaceutical-related fields. The company has approximately 5,600 square meters of R&D and production space, with three static ISO 7 clean production workshops (locally static ISO 5) already built. A comprehensive quality system has been established in accordance with ISO13485, FDA QSR820, and China's Good Manufacturing Practice for Medical Devices.